Latest Breaking News On - Anticipated milestones - Page 3 : comparemela.com

Altimmune (ALT) Announces Lean Mass Preservation Data for Pemvidutide

Altimmune (ALT) Announces Lean Mass Preservation Data for Pemvidutide
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Scott harrisVipink gargAltimmune incMetabolic dysfunction associated steatohepatitisChief executive officerChief medical officerAnticipated milestonesFast trackThree months ended decemberIn process researchCall informationInvestor relations

Vigil Neuroscience Reports Fourth Quarter and Full Year

– Reported positive interim data from Phase 2 IGNITE proof-of-concept clinical trial evaluating iluzanebart (VGL101) for treatment of ALSP – – Enrollment.

Petra kaufmannIvana magovMegan mcgrathLeah gibsonDevelopment rd expensesExchange commissionVigil neuroscience incInvestor relations corporate communicationsChief medical officerVigil neuroscienceChief executive officerAnticipated milestonesMonoclonal antibodyMontreal cognitive assessmentOral small moleculeChief medical

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Alex braunJim dohertyDaniel oconnellDrug administrationDevelopment rd expensesDevelopment officerExchange commissionInternational conference on alzheimerClinical developmentAcumen pharmaceuticals incPharmaceuticals reports financial resultsYear ended decemberDanielo connellChief executive officerAnticipated milestonesInternational conference

Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Petra kaufmannLeah gibsonMegan mcgrathIvana magovExchange commissionDevelopment rd expensesInvestor relations corporate communicationsVigil neuroscience incChief medical officerVigil neuroscienceChief executive officerAnticipated milestonesMonoclonal antibodyMontreal cognitive assessmentOral small moleculeChief medical

Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results

– The independent data monitoring committee (IDMC) recommended the continuation of VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma (PDAC), with no safety concerns raised VIRAGE remains on track to complete enrollment in the first.

United statesComunidad autonoma de catalunaTheriva biologicsStevena shallcrossData monitoring committeeCompany annual report on formPancreatic ductal adenocarcinomaChief executive officerProgram highlightsAnticipated milestonesDuctal adenocarcinomaIndependent data monitoring committeeSant joanBarcelona childrenYear ended decemberAnnual report